- Home
- ALLO vs SPRY Comparison
ALLO vs SPRY Comparison
Compare ALLO & SPRY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ALLO | SPRY |
|---|---|---|
| Founded | 2017 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 722.1M | 634.5M |
| IPO Year | 2018 | 2020 |
Fundamental Metrics
Financial Performance| Metric | ALLO | SPRY |
|---|---|---|
| Price | $2.02 | $5.90 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 15 | 1 |
| Target Price | $8.35 | ★ $40.00 |
| AVG Volume (30 Days) | ★ 5.2M | 1.7M |
| Earning Date | 05-07-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 34.09 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $84,278,000.00 |
| Revenue This Year | N/A | $87.40 |
| Revenue Next Year | $142,416.42 | $81.64 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.04 | $4.91 |
| 52 Week High | $4.46 | $13.15 |
Technical Indicators
Market Signals| Indicator | ALLO | SPRY |
|---|---|---|
| Relative Strength Index (RSI) | 50.69 | 47.54 |
| Support Level | $1.87 | $4.96 |
| Resistance Level | $2.25 | $6.58 |
| Average True Range (ATR) | 0.13 | 0.38 |
| MACD | -0.00 | 0.09 |
| Stochastic Oscillator | 38.71 | 61.08 |
Price Performance
Historical ComparisonAbout ALLO Allogene Therapeutics Inc.
Allogene Therapeutics Inc is a clinical stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. Its pipeline includes "off-the-shelf" T cell candidates designed to target cancer cells or eliminate autoreactive cells in patients with autoimmune disorders. Its three core programs are: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID) and Renal Cell Carcinoma (RCC).
About SPRY ARS Pharmaceuticals Inc.
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the commercialization and development of neffy (currently identified in the European Union (EU) and United Kingdom (U.K.) by the trade name EURneffy and in China) for needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. Neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows Neffy to safely provide intranasal delivery of epinephrine at a low dose within the exposures of approved injectable products across a range of dosing conditions.